dc.contributor
Institut Català de la Salut
dc.contributor
[Tarantino P] Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy. [Corti C] Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, Milan, Italy. Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy. [Schmid P] Barts Cancer Institute, Queen Mary University of London, London, UK. [Cortes J] Oncology Department, International Breast Cancer Center (IBCC), Quiron Group, Barcelona, Spain. Medica Scientia Innovation Research (MedSIR), Barcelona, Spain. Breast Cancer Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain. [Mittendorf EA] Division of Breast Surgery, Department of Surgery, Brigham and Women’s Hospital, Boston, USA. Breast Oncology Program, Dana-Farber Cancer Institute, Boston, USA. [Rugo H] University of California San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center Precision Medicine Cancer Building, San Francisco, USA
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Corti, Chiara
dc.contributor.author
Cortés Castan, Javier
dc.contributor.author
Mittendorf, Elizabeth
dc.contributor.author
Schmid, Peter
dc.contributor.author
Rugo, Hope
dc.contributor.author
Tarantino, Paolo
dc.date.accessioned
2025-10-24T09:34:19Z
dc.date.available
2025-10-24T09:34:19Z
dc.date.issued
2022-07-20T10:30:46Z
dc.date.issued
2022-07-20T10:30:46Z
dc.date.issued
2022-02-18
dc.identifier
Tarantino P, Corti C, Schmid P, Cortes J, Mittendorf EA, Rugo H, et al. Immunotherapy for early triple negative breast cancer: research agenda for the next decade. NPJ Breast Cancer. 2022 Feb 18;8:23.
dc.identifier
https://hdl.handle.net/11351/7875
dc.identifier
10.1038/s41523-022-00386-1
dc.identifier
000757838000001
dc.identifier.uri
http://hdl.handle.net/11351/7875
dc.description.abstract
Breast cancer; Drug development; Immunoediting
dc.description.abstract
Càncer de mama; Desenvolupament de medicaments; Immunoedició
dc.description.abstract
Cáncer de mama; Desarrollo de fármacos; Inmunoedición
dc.description.abstract
For decades, the systemic treatment of localized triple negative breast cancer (TNBC) has exclusively relied on chemotherapy. Recent advancements, however, are rapidly reshaping the treatment algorithms for this disease. The addition of pembrolizumab to neoadjuvant chemotherapy has indeed shown to significantly improve event-free survival for stage II–III TNBC, leading to its establishment as new standard of care in this setting. This landmark advancement has however raised several important scientific questions. Indeed, we desperately need strategies to identify upfront patients deriving benefit from the addition of immunotherapy. Moreover, the best integration of pembrolizumab with further recent advancements (capecitabine, olaparib) is yet to be defined. Lastly, extensive efforts are needed to minimize the impact on patients of immune-related adverse events and financial toxicity. The next decade of clinical research will be key to overcome these challenges, and ultimately learn how to optimally integrate immunotherapy in the treatment landscape of TNBC.
dc.description.abstract
Supported by an American-Italian Cancer Foundation Post-Doctoral Research Fellowship.
dc.format
application/pdf
dc.publisher
Nature Research
dc.relation
NPJ Breast Cancer;8
dc.relation
https://doi.org/10.1038/s41523-022-00386-1
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Mama - Càncer - Tractament
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms::Triple Negative Breast Neoplasms
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama::neoplasias de mama triple negativos
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.title
Immunotherapy for early triple negative breast cancer: research agenda for the next decade
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
